Alcon introduces new medical device for dry eye treatment

Article

As an all-in-one handheld device, eyecare practitioners can tailor patients’ needs for MGD treatment in both eyes in approximately 8 to 12 minutes.

Imaging technology enables eyecare practitioners to tailor MGD treatment patients’ needs for treatment in both eyes in approximately 8 to 12 minutes

The Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System can treat patients' needs in 8 to 12 minutes for both eyes. Image credit: Alcon.


Alcon announced Tuesday the launch of its Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System for the treatment of dry eye.

As an all-in-one handheld device, the company’s latest innovation is designed to deliver gentle warming and pressure directly to patients’ eyelids in order to unblock meibomian glands.

Imaging technology enables eyecare practitioners to tailor MGD treatment to patients’ needs in approximately 8 to 12 minutes for both eyes, according to a company news release.

Additionally, patients are able to view both their meibomian glands and treatment through infared imaging and HD video of the procedure. They may also experience results in as little as one week, the company reported.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
© 2025 MJH Life Sciences

All rights reserved.